## UNITED STATES SECURITIES AND EXCHANGE COMMISSION January 30, 2014

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

Dicerna Pharmaceuticals, Inc.

File No. 333-193150 - CF#30562

Dicerna Pharmaceuticals, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the exhibits to a Form S-1 registration statement filed on December 31, 2013, as amended.

Based on representations by Dicerna Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.19	through January 16, 2017
Exhibit 10.20	through December 31, 2016
Exhibit 10.21	through December 31, 2016
Exhibit 10.22	through November 30, 2016

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Elizabeth M. Murphy Secretary